Alexa Homewood joined the corporate department of Ropes & Gray in 2021. Alexa has experience representing public companies and private equity firms and their portfolio companies in connection with mergers & acquisitions, other direct investments, and general corporate governance matters. Since joining Ropes & Gray, Alexa has become a co-chair for the San Francisco Women’s Forum as well as the San Francisco Ropes Multicultural Forum. In her roles as co-chair, she helps create meaningful experiences for the firm’s diverse attorneys. Alexa also organized the San Francisco Latine Lawyers group in 2023.
Alexa graduated as a Berkeley Law Dean’s Fellow from UC Berkeley School of Law.
During law school, Alexa served as Berkeley Law’s Class of 2021 co-president. She also served as the supervising article editor for the Berkeley La Raza Law Journal and as the co-director of the Berkeley Law Alternative Dispute Resolution Team. Additionally, during law school, Alexa worked as a law clerk at the East Bay Community Law Center for the Community Economic Justice unit.
Prior to law school, Alexa worked as a paralegal for a family law firm and assisted with citizenship classes for the International Rescue Committee.
Experience
Matters include representing:
- WellSky Corporation, a portfolio company of TPG Capital, in its $600 million carve-out acquisition of Curaspan Health Group
- Dessert Holdings, a portfolio company of Bain Capital, in its $712.5 million acquisition of Steven Charles
- ConvaTec Inc. in its $125 million acquisition of Triad Life Sciences
- TPG Capital in its $2.2 billion acquisition of ClaimsXten
- GI Partners in its $423 million take-private acquisition of GTY Technology
- North America Central School Bus, a portfolio company of H.I.G. Capital, in its $120 million CAD add-on acquisition of Sharp Bus Lines Limited
- TSG Consumer Partners in its $425 million acquisition of a majority stake in Radiance Holdings
- GI Partners in its $1.09 billion take-private acquisition of Atlas Technical Consultants
- Provention Bio in its $2.9 billion sale to Sanofi